XML 32 R36.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Collaboration and License Agreements (Details) In Millions, unless otherwise specified | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Mar. 31, 2015 USD ($) | Oct. 31, 2014 USD ($) | Oct. 31, 2014 EUR (€) | Mar. 31, 2015 USD ($) | Dec. 31, 2014 USD ($)
Collaboration and License Agreements [Abstract] |  |  |  |  |
Ipsen Maximum Regulatory And Commercial Milestones |  | $ 34 lxrx_IpsenMaximumRegulatoryAndCommercialMilestones |  |  |
Ipsen Maximum Sales Milestones |  |  | 72 lxrx_IpsenMaximumSalesMilestones |  |
Ipsen Total Upfront Payments | 24.5 lxrx_IpsenTotalUpfrontPayments |  |  |  |
Ipsen Revenue Allocated to License Deliverable |  |  |  | 1.4 lxrx_IpsenRevenueAllocatedtoLicenseDeliverable | 21.2 lxrx_IpsenRevenueAllocatedtoLicenseDeliverable
Ipsen Revenue Allocated to Development Deliverable |  | 1.7 lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable |  |  |
Ipsen Revenue Allocated to Committee Deliverable |  | 0.1 lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable |  |  |
Ipsen Revenue Recognized |  |  |  | $ 1.7 lxrx_IpsenRevenueRecognized |

X
- Details
Name: | lxrx_CollaborationAndLicenseAgreementsAbstract
Namespace Prefix: | lxrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments. + References No definition available. + Details
Name: | lxrx_IpsenMaximumRegulatoryAndCommercialMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments. + References No definition available. + Details
Name: | lxrx_IpsenMaximumSalesMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable. + References No definition available. + Details
Name: | lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable. + References No definition available. + Details
Name: | lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable. + References No definition available. + Details
Name: | lxrx_IpsenRevenueAllocatedtoLicenseDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period. + References No definition available. + Details
Name: | lxrx_IpsenRevenueRecognized
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement. + References No definition available. + Details
Name: | lxrx_IpsenTotalUpfrontPayments
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration